Mesangial cells are the structural scaffolding of the glomerulus, the tuft of capillaries where blood is filtered. Keeping that scaffolding intact is energetically expensive, and the cells rely heavily on mitochondria to supply ATP. Earlier work from the same group had established that BMP4, a member of the TGF-beta signaling family, rises in diabetic kidneys and drives mesangial cells to overproduce type IV collagen and other matrix components through the ALK-Smad1 pathway. What remained unknown was whether BMP4 also interfered with the cells’ energy metabolism, and if so, by what mechanism.

To find out, the team turned to a classic animal model: mice given low-dose streptozotocin over five consecutive days to destroy their insulin-producing beta cells, producing sustained hyperglycemia. Six months after the first injection, mice with fasting glucose above 400 milligrams per deciliter were analyzed. Their kidneys showed the expected hallmarks of diabetic nephropathy, including elevated urinary albumin excretion and mesangial matrix expansion visible with silver staining. But electron microscopy also revealed something subtler: the mitochondria inside mesangial cells were swollen, and their internal cristae, the folded membranes where the electron transport chain operates, were disrupted.

The molecular readouts told a consistent story. Mitochondrial DNA copy number, a proxy for mitochondrial abundance, fell in the diabetic kidneys, as did the activity of cytochrome c oxidase, a key enzyme complex of the respiratory chain. Expression of Pink1 and Park2, the genes encoding the PINK1-Parkin mitophagy machinery that tags damaged mitochondria for destruction, was downregulated. So were Ppargc1a, the gene for the master mitochondrial biogenesis regulator PGC-1alpha, and its downstream targets Tfam, Cox4i1, and Atp5a1. Protein levels of Parkin and TOM20, a marker of the outer mitochondrial membrane, dropped in parallel.

In cultured mouse mesangial cells, the researchers could isolate BMP4’s contribution directly. Bathing the cells in recombinant BMP4 for 24 hours reproduced nearly the entire mitochondrial phenotype seen in the diabetic animals: mtDNA copy number fell, cytochrome c oxidase activity declined, oxygen consumption dropped, ATP production shrank, mitochondrial membrane potential collapsed, and cellular antioxidant capacity weakened. Parkin and TOM20 protein levels fell alongside the mRNA changes. The team also confirmed that high glucose alone, at 30 millimolar, impairs mesangial mitochondrial function, consistent with earlier reports in human mesangial cells, but BMP4 was tested as a specific upstream mediator whose levels rise in the diabetic kidney.

The causal chain became clearer when the researchers manipulated the pathway. Adding LDN-193189, a selective inhibitor of the BMP type I receptors ALK2 and ALK3, prevented BMP4 from suppressing Parkin and the mitochondrial genes, and preserved mtDNA copy number and membrane potential. It also blocked BMP4’s induction of the matrix genes Col4a1 and Col1a1, confirming that the inhibitor was effectively shutting down BMP signaling. Conversely, silencing Parkin with siRNA in otherwise healthy mesangial cells mimicked the BMP4 phenotype, reducing mtDNA copy number, respiratory chain activity, oxygen consumption, ATP levels, and membrane potential, and downregulating PGC-1alpha and its targets.

The most striking experiment involved Parkin overexpression. The team generated mesangial cell lines that constitutively produce Parkin from a transfected gene. In these cells, BMP4 could no longer push Parkin levels down, and the downstream consequences largely evaporated: PGC-1alpha and mitochondrial gene expression stayed up, mtDNA copy number was maintained, cytochrome c oxidase activity and ATP production were preserved. Because the overexpression was so strong, the authors note that quantitative comparisons of Parkin protein between overexpressing and control cells were not appropriate, and they caution that constitutive expression may alter normal regulatory modes, leaving open the possibility of post-transcriptional effects.

The findings position BMP4 as a dual-threat signal in diabetic kidney disease. On one hand, it promotes the structural pathology of mesangial expansion through Smad1-mediated matrix production. On the other, it appears to erode the metabolic foundation of the very cells doing that remodeling. The authors suggest that BMP4 may therefore be involved in both the structural and metabolic alterations of diabetic nephropathy, and that disrupted mitochondrial homeostasis accompanied by decreased Parkin expression could represent a candidate therapeutic pathway.

Therapeutically, the emphasis falls on restoring Parkin function rather than supplying the protein itself, since Parkin works as an intracellular E3 ubiquitin ligase. Prior studies have shown that the mitochondria-targeted antioxidant MitoQ can restore PINK1-Parkin expression through the Nrf2 pathway and ameliorate renal injury in diabetic kidney disease, while FoxO1 activation promotes PINK1-Parkin-mediated mitophagy and protects podocytes. Whether such interventions also influence upstream BMP4 expression remains to be determined.

The authors are careful about the limits of their short communication. The link between Parkin reduction and mitochondrial changes was assessed mainly at the level of gene expression and functional phenotypes, without directly measuring mitophagy flux or the intermediate molecular steps connecting Parkin to PGC-1alpha regulation. BMP signaling was probed only with a pharmacological inhibitor, so the specific receptor subtypes and downstream transcription factors responsible for Parkin suppression remain unidentified. The in vivo analysis examined whole kidney tissue rather than isolated mesangial cells, the temporal relationship between Parkin loss and mitochondrial dysfunction was not established, and no in vivo interventions were tested. Reactive oxygen species and inflammatory cytokines were not quantified, and a direct comparison between high-glucose and BMP4 stimulation was not performed. Still, the convergence of evidence from diabetic mouse kidneys, BMP4-treated cells, Parkin knockdown, and Parkin overexpression makes a compelling case that a fibrosis signal and a mitochondrial quality-control protein are entangled in the progression of diabetic kidney disease, and that untangling them may point toward new ways to protect the failing kidney.

Subject of Research: Role of BMP4-induced Parkin downregulation in mitochondrial dysfunction of mesangial cells in diabetic nephropathy

Article Title: Bone morphogenetic protein 4-associated mitochondrial dysfunction in diabetic nephropathy involves Parkin downregulation

Article References: Tamaki, M., Tominaga, T., Hasegawa, K., Kida, T., Miyakami, S., Shimizu, I., Yamaguchi, S., Minato, M., Nagai, K., & Wakino, S. (2026). Bone morphogenetic protein 4-associated mitochondrial dysfunction in diabetic nephropathy involves Parkin downregulation. Frontiers in Clinical Diabetes and Healthcare, 7, Article 1860424. https://doi.org/10.3389/fcdhc.2026.1860424

Image Credits: AI Generated

DOI: 10.3389/fcdhc.2026.1860424

Keywords: diabetic nephropathy, BMP4, Parkin, mitochondrial dysfunction, mesangial cells, mitophagy, PGC-1alpha, kidney disease, fibrosis, ATP production, ALK inhibitor, streptozotocin model

The clearest thread running through the collection concerns inflammation, and in particular whether modern diabetes drugs do more than lower glucose. In one of the largest analyses included, Alrasheed and colleagues pooled evidence from 40 randomized controlled trials covering 6,029 participants and found that glucagon-like peptide-1 receptor agonists, the drug class behind blockbuster therapies such as semaglutide, significantly reduced major inflammatory biomarkers, most notably C-reactive protein and tumor necrosis factor-alpha. That effect was observed beyond the drugs’ established glycemic control, supporting the idea that part of their cardiovascular benefit may stem from dampening chronic low-grade inflammation rather than from sugar lowering alone. The finding adds mechanistic weight to clinical observations that these agents protect organs in ways that glucose numbers cannot fully explain.

Inflammation in diabetes is not uniform, however, and a second study underscored just how heterogeneous the immune landscape can be at the moment of diagnosis. Tleumagambetova and colleagues examined the balance between interleukin-1beta, a potent pro-inflammatory cytokine, and its natural brake, the interleukin-1 receptor antagonist, in adults newly diagnosed with diabetes. They found lower circulating levels of the receptor antagonist and a higher pro- to anti-inflammatory ratio in individuals who tested positive for islet autoantibodies, markers more often associated with autoimmune forms of the disease. The result suggests that immunometabolic heterogeneity exists right from disease onset, meaning that two patients with identical glucose profiles may sit on very different inflammatory trajectories and may require different therapeutic strategies.

Hypoxia, the cellular response to low oxygen, provides another critical link between metabolic stress and organ damage. In a systematic review and meta-analysis, Su and colleagues examined peripheral blood levels of hypoxia-inducible factor-1alpha, or HIF-1alpha, a master transcriptional regulator switched on when cells sense oxygen deprivation. They found associations between elevated circulating HIF-1alpha and adverse metabolic indices reflecting pancreatic beta-cell dysfunction and insulin resistance. In a companion meta-analysis, the same team extended the analysis to HIF-1alpha alongside sirtuin 1, an NAD-dependent deacetylase central to cellular stress resistance, and vascular endothelial growth factor, the principal driver of new blood vessel formation, revealing altered hypoxic and vascular adaptive responses across diabetic complications.

The authors of the editorial caution, however, that these findings must be interpreted carefully. Circulating markers of hypoxic signaling do not necessarily mirror what is happening inside target tissues, where HIF-1alpha may behave very differently depending on cell type and disease stage. Distinguishing blood-borne signals from tissue-specific signaling is, they argue, an essential next step if researchers hope to understand whether the hypoxic response in diabetes is a protective adaptation that has gone awry or a direct contributor to pathology. The distinction matters enormously for drug development, because blindly activating or suppressing HIF-1alpha could do harm if the biology is misread.

At the cellular level, the collection homes in on mitochondria, the power plants whose dysfunction sits at the intersection of metabolic stress and organ injury. Tamaki and colleagues investigated bone morphogenetic protein 4, or BMP4, a signaling molecule previously associated with scarring and extracellular matrix production in diabetic nephropathy, the kidney complication that remains a leading cause of dialysis worldwide. They demonstrated that BMP4 stimulation led to downregulation of Parkin, a protein responsible for tagging damaged mitochondria for removal, and to impaired mitochondrial homeostasis in mesangial cells, the support cells of the kidney’s filtering units. Crucially, both ALK inhibition and Parkin overexpression ameliorated several of these mitochondrial abnormalities, extending BMP4’s role beyond matrix production into the realm of mitochondrial quality control.

Not every intervention tested in the collection produced clean answers, and that may be its most scientifically honest feature. Kubo and colleagues compared the selective lipid-lowering agent pemafibrate against the omega-3 fatty acid eicosapentaenoic acid in patients with both type 2 diabetes and hypertriglyceridemia. Pemafibrate achieved a greater reduction in malondialdehyde-modified low-density lipoprotein, a chemically altered cholesterol particle implicated in atherosclerosis. Yet urinary 8-hydroxy-2′-deoxyguanosine, a marker of oxidative damage to DNA, and high-sensitivity C-reactive protein did not differ significantly between the two treatments. The takeaway, according to the editors, is that oxidative stress is biologically heterogeneous, and that reading a single biomarker as a proxy for the body’s entire redox state invites misleading conclusions.

Nutrition and environment also emerge as modifiable levers. Wang and colleagues applied machine-learning approaches to dietary oxidative balance, the ratio of antioxidant to pro-oxidant components in the diet, and identified vitamin E, magnesium, and beta-carotene among the factors associated with renal impairment defined by the urinary albumin-to-creatinine ratio, a standard clinical measure of kidney damage. Exploratory experiments implicated AKT-related signaling, a central growth and survival pathway, as a possible mechanistic mediator. On the environmental front, Zhang and colleagues reported interactions between temperature, humidity, and tongue color in patients with diabetes, with the associations particularly pronounced among individuals with cardiovascular complications, hinting that environmental stress may interact with impaired microcirculatory adaptation in measurable ways.

The clinical stakes of these molecular networks are laid bare in two studies of established complications. Rashwan and colleagues, studying 387 patients with diabetic peripheral neuropathy, identified smoking, a history of foot ulceration or amputation, and advanced chronic kidney disease as the factors most strongly associated with loss of protective sensation, the deficits that precede the foot ulcers and amputations that make diabetes one of the leading causes of limb loss worldwide. Meanwhile, Srithongchai and colleagues reviewed the advanced glycation end-product and its receptor, the AGE-RAGE axis, as a pathogenic signaling network. Membrane-bound RAGE, they argue, serves as an interface connecting carbonyl and oxidative stress with inflammatory activation, while soluble RAGE isoforms may act as decoy receptors that blunt the damage. Importantly, the review reframes RAGE’s physiological function as the selective modulation of pathogenic signaling rather than indiscriminate receptor activity, suggesting that future therapies should aim for precision rather than blanket blockade.

Taken together, the ten contributions portray diabetic complications as products of an interconnected network operating across tissues and disease stages rather than the work of any single pathway. Metabolic overload, oxidative and carbonyl stress, inflammation, hypoxic responses, mitochondrial dysfunction, environmental influences, and impaired adaptive mechanisms all feed into one another, which is why changes in any individual molecular marker cannot be interpreted in isolation. The editors argue that future research should focus on defining the molecular switches that determine whether stress responses remain adaptive or turn pathogenic, on integrating complementary biomarkers across biological compartments, and on testing whether selective modulation of these pathways can translate into genuine prevention of organ injury. If successful, such mechanism-based strategies could move the management of type 2 diabetes beyond the glucose meter, toward treating the web of stress and inflammation that ultimately destroys organs.

Subject of Research: Oxidative stress and inflammatory pathways driving organ complications in type 2 diabetes

Article Title: Editorial: Oxidative stress and inflammation in type 2 diabetes: pathways to organ complications

Article References: Otoda, T., Miyake, T., Yagi, S., Aihara, K.-I., & Kanasaki, K. (2026). Editorial: Oxidative stress and inflammation in type 2 diabetes: pathways to organ complications. Frontiers in Clinical Diabetes and Healthcare, 7, Article 1976753. https://doi.org/10.3389/fcdhc.2026.1976753

Image Credits: AI Generated

DOI: 10.3389/fcdhc.2026.1976753

Keywords: type 2 diabetes, oxidative stress, inflammation, GLP-1 receptor agonists, HIF-1alpha, mitochondrial dysfunction, diabetic nephropathy, RAGE, diabetic neuropathy, biomarkers, AGEs, diabetic complications

The research team, led by Tongkai Wu, Jin Yu, Yinfeng Chen, Dongrong Yu, and Jun Ni, assembled a cohort of 905 patients with diabetic kidney disease whose baseline estimated glomerular filtration rate, or eGFR, sat between 15 and just under 60 mL/min/1.73 m², the range defining moderate to severe chronic kidney disease. Enrolment stretched from June 2008 to April 2024, giving the study more than fifteen years of real-world clinical data drawn from a single center. Using the urine albumin-to-creatinine ratio, the standard metric for classifying albuminuria, the researchers divided patients into 176 with NADKD and 729 with the conventional albuminuric form of diabetic kidney disease. Because the two groups differed in many baseline characteristics, the investigators applied propensity score matching in a one-to-one fashion, a statistical technique that pairs patients across groups with similar overall risk profiles, ultimately yielding 151 well-balanced patients in each arm with a median age of 73 years.

The comparison revealed a metabolic fingerprint that sets NADKD apart in striking ways. Patients in the non-albuminuric group had higher serum albumin levels but lower fasting blood glucose, lower total cholesterol, lower glycated hemoglobin, and a lower triglyceride-glucose index, a composite marker of insulin resistance. In plain terms, these patients carried a milder metabolic derangement than their albuminuric counterparts, yet their kidneys had still declined to the same functional territory. That paradox is precisely what makes NADKD clinically perplexing: if chronic hyperglycemia and dyslipidemia drive kidney injury in diabetes, why do some patients with comparatively better metabolic control lose kidney function while their urine remains essentially albumin-free?

One of the study’s most eye-catching findings points toward an answer that lies outside the kidney itself. Nearly sixty percent of the NADKD patients, 59.6 percent, had macrovascular disease, meaning clinically manifest atherosclerotic conditions such as coronary artery disease, cerebrovascular disease, or peripheral arterial disease, compared with only 39.7 percent of the albuminuric group, a difference that reached statistical significance at P equals 0.001. This inverted burden, heavier vascular disease in the group with lighter microvascular footprints, suggests that non-albuminuric diabetic kidney disease may not simply be an early or attenuated version of classic diabetic nephropathy but a biologically distinct entity in which large-vessel pathology and ischemic injury to kidney tissue play a proportionally larger role than the microvascular mechanisms classically blamed for diabetic kidney failure.

The prognostic implications of that distinction are substantial. Kaplan-Meier survival analysis, the standard method for tracking event-free survival over time, showed significantly better renal survival in the NADKD group, with a P value below 0.001. The annual rate of eGFR decline told the same quantitative story: patients with non-albuminuric disease lost kidney function at 0.747 mL/min/1.73 m² per year on average, whereas albuminuric patients declined at 3.224 mL/min/1.73 m² per year, more than four times faster. Slippage of that magnitude compounds mercilessly; a patient losing three-plus units annually from a baseline of 40 will typically cross the threshold toward dialysis within a decade, while a slower decliner may never reach end-stage disease within their lifetime. All-cause mortality, intriguingly, did not differ significantly between the groups, with a P value of 0.054 that narrowly missed conventional significance, hinting that while the kidneys fare differently, overall survival risk may be comparable once the vascular burden is accounted for.

To move from description to prediction, the researchers built a multivariable Cox proportional hazards model, the workhorse tool for identifying independent risk factors for time-to-event outcomes. In that analysis, macrovascular disease emerged as an independent risk factor for composite renal outcomes, carrying a hazard ratio of 4.19 with a 95 percent confidence interval spanning 1.45 to 12.09 and a P value of 0.008. A hazard ratio above four is clinically meaningful: after adjusting for other variables, patients with macrovascular disease faced more than quadruple the instantaneous risk of a adverse renal event compared to those without. The final parsimonious model contained just four variables, age, sex, baseline eGFR, and macrovascular disease, an appealingly simple set that any nephrologist or endocrinologist could assemble from a routine clinic visit.

The performance statistics of that model were reported with a methodological rigor that deserves attention. The apparent concordance index, or C-index, a measure of how well the model ranks risk across patients, reached 0.762. Because apparent performance in the development dataset tends to be optimistically biased, the team applied bootstrap internal validation, resampling the data 1,000 times to estimate and subtract that optimism. The optimism-corrected C-index settled at 0.744, still comfortably in the range considered acceptable to good for clinical prediction models. Time-dependent analyses added further support: the area under the receiver operating characteristic curve for predicting renal outcomes at three years was 0.828, and at five years it was 0.745. In practical terms, the model correctly discriminates high-risk from low-risk patients well enough to justify early intensified monitoring in those flagged as vulnerable, particularly those with documented macrovascular disease.

The conceptual takeaway is potentially practice-changing. Screening algorithms built around albuminuria may systematically miss patients whose kidneys are quietly deteriorating without a protein leak, delaying both diagnosis and the initiation of kidney-protective therapies. The study’s authors argue that NADKD represents a distinct subtype of diabetic kidney disease, one characterized by a heavier macrovascular burden and a slower but real trajectory of renal decline. That framing carries a direct clinical message: in a patient with diabetes and falling eGFR, a normal urine albumin-to-creatinine ratio should reassure nobody. Instead, the presence of coronary, cerebral, or peripheral atherosclerosis in such patients should itself be read as a renal risk signal, and serial eGFR monitoring should be treated as the primary surveillance tool for this population in the way albumin measurements have long been for others.

As with all single-center retrospective studies, caveats apply. The cohort came from one hospital in Hangzhou, China, and the retrospective design means classification depended on the quality of routine clinical documentation rather than protocolized assessments; residual confounding by unmeasured variables can never be fully excluded even with propensity matching. Kidney biopsies, the diagnostic gold standard that would confirm whether the pathology of NADKD truly differs at the tissue level, were not part of the analysis, so the mechanistic interpretation, that large-vessel ischemia substitutes for microvascular injury, remains a well-supported hypothesis rather than a histologically proven fact. The prediction model, validated internally by bootstrap but not yet in an external independent cohort, will need confirmation in multi-center populations before it can be embedded in guidelines.

Nevertheless, the study lands at a moment when the clinical stakes of diabetic kidney disease are rising sharply. Global diabetes prevalence continues to climb, kidney replacement therapy remains enormously expensive, and newly available kidney-protective drugs, from SGLT2 inhibitors to non-steroidal mineralocorticoid receptor antagonists, work best when started early. Identifying which patients need those therapies most urgently, including the non-albuminuric minority that traditional screening overlooks, could translate directly into preserved kidney function and avoided dialysis. If follow-up studies confirm that macrovascular disease reliably stratifies renal risk in NADKD, the humble urine dipstick may finally have to share its throne with a stethoscope, an electrocardiogram, and a routinely calculated eGFR slope, a small shift in workflow with the potential to change outcomes for millions of patients whose kidneys fail without ever leaking a trace of albumin.

Subject of Research: Clinical characteristics and prognosis of non-albuminuric diabetic kidney disease in patients with reduced kidney function

Article Title: Clinical characteristics and prognosis of non-albuminuric diabetic kidney disease: a single-center retrospective cohort study

Article References: Wu, T., Yu, J., Chen, Y., Yu, D., & Ni, J. (2026). Clinical characteristics and prognosis of non-albuminuric diabetic kidney disease: a single-center retrospective cohort study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02646-8

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02646-8

Keywords: diabetic kidney disease, non-albuminuric diabetic kidney disease, chronic kidney disease, macrovascular disease, eGFR decline, albuminuria, renal prognosis, risk prediction model, propensity score matching, BMC Endocrine Disorders, diabetic nephropathy, retrospective cohort study

Diabetic nephropathy develops when prolonged exposure to high blood sugar damages the delicate filtering units of the kidneys, the glomeruli. Clinically, it announces itself through rising levels of albumin in the urine and a gradual decline in the estimated glomerular filtration rate, the standard measure of kidney function. Because the condition often progresses silently for years before symptoms appear, clinicians have long sought biomarkers that could flag patients at risk before irreversible damage sets in. Inflammation has been a prime suspect: hyperglycemia triggers the production of pro-inflammatory cytokines, and these signaling molecules in turn promote the fibrosis, thickening of basement membranes, and vascular dysfunction that characterize the failing diabetic kidney.

The research team, led by Olimjan Nazirkulov of the Institute of Immunology and Human Genomics of the Academy of Sciences of the Republic of Uzbekistan, together with colleagues from Samarkand State Medical University, Tashkent State Medical University, and Kimyo International University, recruited 227 patients with type 2 diabetes. Of these, 95 had no microvascular complications, while 132 had diabetic nephropathy. The investigators collected demographic, clinical, laboratory, and medication data, and measured hs-CRP and IL-6 concentrations in the blood. The study protocol was approved by the Institutional Review Board of the Institute of Immunology and Human Genomics, and all participants provided written informed consent in accordance with the Declaration of Helsinki.

The differences between the two groups were striking. Patients with diabetic nephropathy had a median hs-CRP concentration of 7.50 milligrams per liter, compared with 4.54 milligrams per liter in patients without microvascular complications. Their median IL-6 levels were similarly elevated, at 13.30 picograms per milliliter versus 8.40 picograms per milliliter. Both differences were highly statistically significant, with P values below 0.001. Beyond the inflammatory markers, the nephropathy group was also older, had lived with diabetes for longer, and more frequently suffered from hypertension, all factors known to compound kidney risk.

To determine whether these inflammatory markers carried independent predictive weight, the researchers constructed five multivariable logistic regression models, progressively adjusting for potential confounders. In the fully adjusted model, each unit increase in hs-CRP was associated with a 31 percent higher odds of diabetic nephropathy, with an adjusted odds ratio of 1.31 and a 95 percent confidence interval of 1.07 to 1.59. IL-6 proved an even stronger signal: each unit increase carried a 50 percent higher odds of nephropathy, with an adjusted odds ratio of 1.50 and a confidence interval of 1.31 to 1.72. Longer diabetes duration, hypertension, and higher fasting plasma glucose levels were also independently associated with the complication.

Perhaps the most technically compelling result concerns how much the inflammatory markers improved risk prediction. The researchers evaluated model discrimination using receiver operating characteristic (ROC) curve analysis and pairwise comparisons of the area under the curve (AUC). A clinical model built on conventional risk factors alone achieved an AUC of 0.814, already respectable performance. When hs-CRP and IL-6 were added, the AUC climbed to 0.943, a substantial gain that pushed the model into the range of excellent discrimination. Because such gains can be inflated by overfitting, the team performed internal validation using 1,000 bootstrap resamples; the optimism-corrected AUC remained at 0.921, indicating that the improvement was robust rather than a statistical artifact.

Calibration, the question of whether a model’s predicted probabilities match observed outcomes, was assessed through calibration plots, Brier scores, and the Hosmer–Lemeshow test, providing a methodologically thorough evaluation that goes beyond the discrimination statistics often reported in isolation. Group comparisons in the study were performed using the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables, appropriate choices given that biomarker distributions in biological samples are typically skewed. Statistical significance was defined as a P value below 0.05 throughout.

The study’s setting matters. Central Asian populations have been markedly underrepresented in diabetes research, and evidence linking inflammatory biomarkers to diabetic nephropathy has come overwhelmingly from East Asian, European, and North American cohorts. By demonstrating that the hs-CRP and IL-6 associations hold in an Uzbekistani patient population, the researchers provide a valuable data point from a region where diabetes prevalence is rising and nephrology resources are often stretched. The work also benefited from institutional support, with the authors acknowledging the Samarkand Branch of the Republican Specialised Scientific and Practical Medical Centre of Endocrinology and the Institute of Immunology and Human Genomics for organizational and technical assistance. The study received no specific external funding, and the authors declare no competing interests.

Mechanistically, the findings fit a coherent biological narrative. IL-6 is a pleiotropic cytokine released by immune cells, adipose tissue, and damaged endothelium; it drives hepatic production of CRP, which is why the two markers tend to rise together. In the diabetic kidney, IL-6 signaling has been implicated in mesangial cell proliferation, increased vascular permeability, and the activation of fibrotic pathways that progressively scar the glomeruli. hs-CRP, meanwhile, serves as a stable, easily measured readout of systemic inflammatory burden. The fact that both markers remained significant after adjustment for glycemic control, blood pressure, and diabetes duration suggests that inflammation captures risk information that conventional clinical variables miss, consistent with the hypothesis that inflammatory pathways contribute actively to nephropathy rather than simply reflecting it.

The authors are careful to frame their conclusions appropriately. As a cross-sectional study, the work captures a single moment in time and cannot establish whether elevated hs-CRP and IL-6 precede kidney damage or accompany it; reverse causation, in which declining kidney function itself drives inflammation, remains a plausible alternative explanation. The researchers note that prospective and externally validated studies are needed to determine the clinical utility of hs-CRP and IL-6 before the markers can be considered for routine clinical risk assessment. Still, the magnitude of the associations, the near doubling of model performance, and the bootstrap-validated robustness make a strong case that these inexpensive, widely available blood tests deserve a place in future longitudinal trials. If those trials confirm the signal, a simple pair of measurements could one day help clinicians identify which of their diabetic patients needs the closest kidney surveillance, years before dialysis becomes the only option.

Subject of Research: Associations of inflammatory biomarkers hs-CRP and IL-6 with diabetic nephropathy in type 2 diabetes patients

Article Title: Associations of hs-CRP and interleukin-6 with diabetic nephropathy in patients with type 2 diabetes mellitus: a cross-sectional study from Uzbekistan

Article References: Nazirkulov, O., Abdullayeva, N., Ziyadullaev, S., Tulyaganova, D., Kodirov, A., Kadirov, J., Eshbayeva, K., Ishonhajaev, H., Akhmedov, A., Nasretdinova, M., Samibaeva, U., & Ruzimurodov, N. (2026). Associations of hs-CRP and interleukin-6 with diabetic nephropathy in patients with type 2 diabetes mellitus: a cross-sectional study from Uzbekistan. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02515-4

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02515-4

Keywords: type 2 diabetes, diabetic nephropathy, hs-CRP, interleukin-6, inflammation, chronic kidney disease, biomarkers, risk prediction, Uzbekistan, cross-sectional study, logistic regression, microvascular complications

The research team, led by Leonard D. Browne and Austin G. Stack of the University of Limerick, together with colleagues at University College Cork, the University of Bristol and partner hospitals, performed a retrospective cross-sectional study of every hospital discharge in the Republic of Ireland recorded in 2022. They used the Hospital In-Patient Enquiry database, known as HIPE, which captures demographic, clinical and administrative information on all admissions to Irish public hospitals. To isolate the specific contribution of chronic kidney disease, the researchers excluded infant admissions and cases in which dialysis or kidney transplantation were the principal reason for the stay, since those represent the treatment of established kidney failure rather than the broader disease spectrum.

The headline figures are striking. A total of 35,409 hospitalisations involving 24,110 individual patients were linked to chronic kidney disease, accounting for 422,738 bed-days and €320.3 million in expenditure. The mean length of stay was 11.9 days, far longer than the typical acute admission, which reflects the complexity of patients whose failing kidneys interact with heart disease, diabetes, infection and other organ dysfunction. Men accounted for the majority of admissions at 58.9 percent and a similar share of costs at 59.9 percent, while patients aged 75 to 84 years represented the largest single group, responsible for 30.0 percent of admissions and 30.8 percent of total expenditure.

Perhaps the most consequential finding for health service planners is the dominance of emergency admissions. Some 71.2 percent of kidney disease-related hospitalisations arrived through emergency departments rather than planned pathways, and 69 percent of the patients held medical cards, an Irish means-tested entitlement that signals substantial socioeconomic disadvantage. Emergency-driven care is inherently more expensive and less efficient than scheduled management, and its predominance suggests that many patients are reaching hospital only after their condition has deteriorated to a crisis point, rather than being stabilised through earlier outpatient intervention.

The study also mapped the clinical company that chronic kidney disease keeps. Among patients whose records carried a CKD code, diabetic nephropathy was the most common accompanying diagnosis at 49.5 percent, followed by tubulo-interstitial diseases at 9.1 percent, other disorders of the kidney and ureter at 6.7 percent, and glomerular diseases at 4.3 percent. That nearly half of these hospitalised patients had diabetes-related kidney damage underscores the entanglement of two of the fastest-growing chronic disease epidemics, and it points directly at prevention opportunities in diabetes management.

When chronic kidney disease appeared as a secondary diagnosis rather than the principal reason for admission, the pattern of primary conditions was revealing. Standardised to rates per 100,000 population, the leading principal diagnoses were disorders of the urinary system at 6,442, acute kidney failure at 3,764, type 1 diabetes at 2,540, type 2 diabetes at 2,489, heart failure at 2,362, other sepsis at 2,199, acute lower respiratory infections at 1,831, and unspecified pneumonia at 1,710. In other words, kidney disease shadows the conditions that fill acute medical wards: infections, cardiac decompensation and metabolic crises. This is the clinical signature of a multisystem disease, one in which declining renal function amplifies risk across the cardiovascular, immune and metabolic systems.

To move beyond simple description, the researchers applied formal statistical modelling. They used generalised linear models to examine associations between patient characteristics and continuous outcomes such as length of stay and cost, and multivariate logistic regression to probe the odds of inpatient death. Three factors emerged as independent drivers of worse outcomes across the board: increasing age, higher scores on the Elixhauser comorbidity index, a widely used weighted measure that tallies the burden of coexisting conditions, and the presence of acute kidney injury, the abrupt deterioration of renal function that frequently complicates hospital stays in patients with pre-existing chronic disease.

The independent association of acute kidney injury with longer stays, higher costs and greater mortality carries a specific clinical message. Acute kidney injury is often preventable through careful medication management, adequate hydration and vigilant monitoring during illness, and patients with chronic kidney disease are particularly vulnerable to it. The finding suggests that inpatient care pathways specifically designed to protect vulnerable kidneys, sometimes called kidney-sparing protocols, could yield measurable savings in both bed-days and lives. It also reinforces the idea that chronic kidney disease should not be managed in isolation but integrated within broader chronic disease programmes that address diabetes, cardiovascular risk and infection prevention together.

The financial arithmetic gives the findings their policy weight. At €320.3 million for a single year, kidney disease-related hospitalisation represents a substantial slice of Irish acute hospital spending, and the concentration of that spending in older, multimorbid patients means the burden is likely to grow as the population ages. The authors argue that integrating chronic kidney disease management within existing chronic disease programmes, alongside preventive strategies and optimised inpatient care pathways, offers realistic opportunities to ease the broader healthcare burden and improve patient outcomes. Earlier detection and management in primary care, they suggest, could shift care away from expensive emergency admissions.

The study was supported with funding from the Health Research Board under a grant examining disparities in health outcomes of chronic kidney disease between men and women in the Irish health system, and it used strictly controlled anonymised files provided by the Healthcare Pricing Office through the National Kidney Disease Surveillance System. Ethical approval was granted by the University Hospital Limerick Research Ethics Committee, with the requirement for explicit consent waived because the dataset was fully anonymised. The authors declare no competing interests. For a country grappling with hospital overcrowding and rising chronic disease, the message of this analysis is unambiguous: the kidneys may be small organs, but the cost of ignoring their failure is written in hundreds of thousands of bed-days and hundreds of millions of euro every year.

Subject of Research: Hospitalisation burden, mortality and costs of chronic kidney disease in Ireland

Article Title: The Hospital Burden of Chronic Kidney Disease in Ireland: A National Analysis of Healthcare Utilisation, Mortality and Costs

Article References: Browne, L. D., O’Keeffe, L. M., Buckley, C. M., Eustace, J. A., & Stack, A. G. (2026). The Hospital Burden of Chronic Kidney Disease in Ireland: A National Analysis of Healthcare Utilisation, Mortality and Costs. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15681-x

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15681-x

Keywords: chronic kidney disease, hospitalisation, healthcare costs, acute kidney injury, Ireland, HIPE database, diabetic nephropathy, inpatient mortality, length of stay, multimorbidity, health services research, emergency admissions

Oral frailty is a concept that has gained momentum in geriatric medicine over the past decade. It describes an age-related, potentially reversible decline in oral function, encompassing diminished chewing ability, difficulty swallowing, reduced tongue and lip strength, a dry mouth, and a tendency to avoid harder foods. Unlike tooth loss alone, oral frailty is a functional syndrome, capturing how well the entire oral apparatus performs rather than simply counting missing teeth. Researchers have already linked it to malnutrition, sarcopenia, cognitive decline, and cardiovascular risk. What has remained far less clear is whether oral frailty tracks with kidney abnormalities, particularly in older adults with type 2 diabetes, a population in which both oral deterioration and diabetic kidney disease are common and often progress silently for years.

To probe that question, the research team led by Xiaoling Deng and Wenbo Xia, with Lili Shi as corresponding author, recruited 201 hospitalized patients aged 60 and older who had been diagnosed with type 2 diabetes. The study was approved by the hospital’s ethics committee and conducted in accordance with the Helsinki declaration, with written informed consent from all participants. Each patient underwent a structured oral assessment using two validated instruments: the Oral Frailty Five-Item Checklist, known as OF-5, and the eight-item Oral Frailty Index, or OFI-8. The OF-5 is a rapid screening tool that asks about practical difficulties such as chewing tough foods, swallowing, and social dining, while the OFI-8 provides a more granular functional profile. Alongside these oral measures, the researchers collected standard clinical data, including age, sex, diabetes duration, glycated hemoglobin, and hypertension status, as well as laboratory values covering renal function, blood counts, and inflammatory indices.

The results were striking. According to the OF-5 checklist, 46.3 percent of the participants screened positive for oral frailty, meaning nearly one in two older diabetic inpatients showed measurable decline in oral function. The OFI-8 classified 35.3 percent as high risk. When the researchers cross-referenced these oral findings with kidney measures, a consistent pattern emerged. Patients positive on the OF-5 had roughly 4.7 times higher odds of having an estimated glomerular filtration rate below 90 milliliters per minute per 1.73 square meters, the conventional threshold indicating reduced kidney filtration capacity. Even more pronounced was the association with albuminuria: OF-5 positivity was linked to about 7.1 times higher odds of a first-morning urinary albumin concentration at or above 30 milligrams per liter, a level that signals glomerular damage and is a cornerstone marker for early diabetic kidney disease.

These associations held up after statistical adjustment. The team used multivariable logistic regression models that controlled for age, sex, diabetes duration, HbA1c, and hypertension, the major clinical covariates that typically confound relationships between diabetes complications. The fact that oral frailty remained independently associated with both renal outcomes after these adjustments suggests the link is not merely a byproduct of older age, longer disease duration, poorer glycemic control, or coexisting high blood pressure, each of which independently damages kidneys. The magnitude of the adjusted odds ratios, particularly for urinary albumin, is notable for a screening tool that costs nothing to administer and takes only moments to complete.

Perhaps the most technically interesting part of the study is how the authors quantified whether oral frailty adds genuine predictive value beyond routine clinical information. They built a clinical base model using the standard covariates and then compared it with extended models that additionally incorporated the OF-5 or OFI-8 scores. Model performance was measured with the area under the receiver operating characteristic curve, or AUC, and was internally validated using 1,000 bootstrap resamples with optimism correction, a rigorous approach that guards against the inflated performance estimates that plague many small clinical prediction studies. For the eGFR outcome, adding the OF-5 raised the optimism-corrected AUC from 0.713 to 0.771. For elevated urinary albumin, the base model’s AUC of 0.675 improved to 0.783 with the OF-5 and to 0.779 with the OFI-8. Optimism-corrected calibration slopes for the extended models ranged from 0.852 to 0.887, indicating reasonably faithful agreement between predicted and observed risks.

The biological plausibility of a mouth-kidney connection rests on several converging mechanisms. Chronic low-grade inflammation is a central suspect: periodontal disease and oral dysfunction can elevate systemic inflammatory burden, and the inflammatory indices measured in the study, including the systemic immune-inflammation index and the systemic inflammation response index, reflect this axis. Sustained inflammation promotes endothelial injury in glomerular capillaries, accelerating albumin leakage. Another pathway involves nutrition. Oral frailty pushes patients toward soft, often processed foods and away from protein-rich and fibrous options, potentially driving the protein-energy malnutrition and sarcopenia that are themselves established risk factors for faster kidney decline. Shared vascular pathology offers a third explanation: the microvascular damage that impairs glomerular filtration in diabetes also compromises blood flow to the periodontal tissues and salivary glands, so oral decline and renal decline may simply be parallel manifestations of the same underlying vascular injury.

The authors are careful to spell out the limits of what their data can show. This was a single-center, cross-sectional study of hospitalized patients, a design that captures a snapshot in time and cannot establish whether oral frailty precedes kidney dysfunction or results from it. Reverse causation is plausible, since patients with advanced chronic kidney disease often suffer uremic taste changes, xerostomia, and reduced appetite that could worsen oral function. The inpatient setting also means the sample may overrepresent patients with more severe disease, limiting generalizability to community-dwelling older adults. The authors explicitly state that the findings do not establish causality, prospective predictive utility, or external validity, and the modest improvement in discrimination, while statistically meaningful, reflects a limited covariate set rather than a fully specified clinical model.

Even with those caveats, the clinical implications are compelling. Diabetic kidney disease affects an estimated 40 percent of people with diabetes and is the leading cause of end-stage renal disease worldwide, yet it is frequently diagnosed late because early stages produce no symptoms. Current screening relies on annual urine albumin testing and serum creatinine measurements, which many patients, particularly in resource-limited settings, do not receive on schedule. A validated oral frailty checklist could serve as an essentially free triage tool: a positive screen in an older diabetic patient might prompt earlier laboratory testing, closer nephrology follow-up, or intensified metabolic management. It could also motivate dental and medical teams to collaborate more systematically, since treating oral frailty through chewing exercises, denture optimization, and nutritional counseling is low-risk and potentially reversible.

Future research will need to determine whether the association holds prospectively, whether oral frailty scores measured in community settings predict incident kidney disease over years, and whether interventions that restore oral function actually slow renal decline. If those questions are answered affirmatively, the humble act of asking an older diabetic patient whether they can chew hard food or swallow comfortably could become a routine part of kidney risk assessment, joining blood pressure cuffs and glucose meters as a first-line instrument in the fight against one of diabetes’ most feared complications. For now, the Harbin study adds a provocative new entry to the growing list of systemic diseases that leave their fingerprints in the mouth, and it challenges clinicians to stop viewing oral health as separate from the rest of metabolic medicine.

Subject of Research: Association between oral frailty and early renal dysfunction in elderly patients with type 2 diabetes

Article Title: Correlation between oral frailty and renal function and urinary microalbumin in elderly patients with type 2 diabetes mellitus

Article References: Deng, X., Xia, W., Huo, D., Zhang, J., Sun, T., & Shi, L. (2026). Correlation between oral frailty and renal function and urinary microalbumin in elderly patients with type 2 diabetes mellitus. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02543-0

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02543-0

Keywords: oral frailty, type 2 diabetes, chronic kidney disease, estimated glomerular filtration rate, urinary albumin, diabetic nephropathy, geriatric medicine, albuminuria, screening, inflammation, BMC Endocrine Disorders, cross-sectional study

The study, led by Emel Tatlı of the Department of Nephrology at Gaziosmanpaşa Training and Research Hospital, University of Health Sciences, together with Tuğba Kip of Abdi İbrahim Pharmaceuticals, enrolled 83 participants: 59 patients with type 2 diabetes, of whom 29 had diabetic nephropathy and 30 did not, and 24 healthy controls. The design was deliberately simple and comparative. By measuring melatonin alongside a panel of oxidative and inflammatory markers in all three groups, the team set out to answer a question that has lingered in the literature for years: is the sleep hormone a bystander in the metabolic chaos of diabetes, or does its depletion track specifically with the kidney damage that diabetes inflicts?

The headline finding concerns the comparison between diabetic patients and healthy controls. Serum melatonin, measured with a validated enzyme-linked immunosorbent assay, averaged 22.00 plus or minus 15.56 nanograms per litre in the diabetic group, against 42.88 plus or minus 29.61 nanograms per litre in the controls, a difference that was highly statistically significant. In other words, people with type 2 diabetes carried roughly half the circulating melatonin of their healthy counterparts. That depletion did not travel alone. Total antioxidant status, a composite measure of the blood’s capacity to neutralise oxidants, was also markedly reduced in the diabetic group, falling from 7.87 to 4.05 millimoles per litre on average.

Curiously, total oxidant status moved in the same direction rather than the opposite one. The diabetic patients showed lower TOS values, 2.33 versus 8.50 micromoles per litre, alongside their lower antioxidant reserves. The authors interpret this apparently paradoxical pairing as evidence of a coupled deficit: when the antioxidant defence system is exhausted, the measurable oxidant burden in serum may also fall, because the reactive species are being consumed in damaging reactions rather than accumulating in the bloodstream. Whatever the precise mechanism, the strong positive correlations between melatonin and both antioxidant and oxidant status, with Spearman coefficients of 0.83 and 0.75 respectively, suggest that the hormone’s circulating level rises and falls in lockstep with the broader redox economy of the blood.

The inflammation data reinforce that picture of systemic metabolic strain. C-reactive protein, the liver-derived acute-phase protein that serves as a standard gauge of low-grade inflammation, was significantly elevated in the diabetic cohort compared with controls. Melatonin’s anti-inflammatory credentials are well established in experimental systems, where it suppresses nuclear factor-kappa B signalling, dampens tumour necrosis factor alpha and interleukin production, and limits neutrophil infiltration. The new findings are consistent with the idea that in established type 2 diabetes, the body’s endogenous melatonin system is running on empty precisely when inflammatory and oxidative pressures are at their highest.

But the story changes when the lens narrows to the kidneys. Within the diabetic cohort itself, neither total antioxidant status nor total oxidant status differed significantly between patients with diabetic nephropathy and those without. And in a result the authors themselves describe as paradoxical, serum melatonin was marginally higher in the nephropathy group, at a p-value of 0.043, the opposite direction to the pattern most researchers would have predicted. Diabetic nephropathy is classically driven by oxidative stress and chronic inflammation, the very processes melatonin is thought to counter. If melatonin depletion were a specific engine of kidney damage, one would expect the lowest levels in the patients with the worst kidneys.

What did separate the nephropathy patients was the conventional renal panel. They had markedly higher urea and creatinine, lower albumin, and higher C-reactive protein than their diabetic peers without kidney involvement. When the researchers constructed receiver operating characteristic curves to test how well each marker discriminated nephropathy, urea performed best, with an area under the curve of 0.805 and a 95 percent confidence interval of 0.696 to 0.897. Estimated glomerular filtration rate followed with an area of 0.737. Melatonin managed only a modest 0.666, well short of what would be needed for a clinically useful diagnostic test. Multivariate logistic regression confirmed that melatonin and the oxidative indices did not independently predict nephropathy once renal function markers were accounted for.

The authors’ conclusion is carefully worded but consequential: melatonin appears to mark the global oxidative and metabolic burden of type 2 diabetes rather than nephropathy specifically. That framing matters for two reasons. First, it cautions against the growing enthusiasm for melatonin as a standalone biomarker of diabetic complications. A hormone that reflects the overall diabetic state cannot, by itself, tell a clinician which organs are being damaged. Second, it tempers expectations for melatonin supplementation as a targeted kidney-protective therapy, at least on the basis of circulating levels. If serum melatonin does not track nephropathy, then simply raising it may not address the local renal pathology, though the authors are careful not to extrapolate beyond their cross-sectional data.

The study’s limitations are those inherent to its design. With 83 participants, it is powered to detect large differences, and the confidence intervals around some estimates are wide. A cross-sectional snapshot cannot establish whether low melatonin precedes kidney damage or follows it, and the marginal melatonin elevation in the nephropathy group may reflect reduced renal clearance of the hormone or confounding by reduced antioxidant capacity in advanced disease. The single-centre recruitment at a Turkish training and research hospital, approved by the local ethics committee with written informed consent from all participants, also limits generalisability. Longitudinal cohorts with serial melatonin measurements would be needed to disentangle cause from consequence.

Even so, the findings land at a moment of intense interest in the redox biology of diabetes. Melatonin research has expanded from sleep medicine into cardiology, oncology and nephrology, fuelled by the hormone’s potent free-radical scavenging and its receptor-mediated signalling pathways. This study offers a useful corrective: in real-world patients with established type 2 diabetes, the endogenous melatonin system is measurably depleted and tightly coupled to antioxidant status, but it is not a window into the kidney. For now, the humble blood urea test remains the better sentinel of diabetic nephropathy, and melatonin’s clinical role in diabetes remains, as the data suggest, that of a systemic marker rather than an organ-specific one.

Subject of Research: Serum melatonin levels in relation to inflammation and oxidative stress in type 2 diabetes and diabetic nephropathy

Article Title: Serum melatonin levels and their relationship with inflammation and oxidative stress in patients with diabetic nephropathy: a cross-sectional case–control study

Article References: Tatlı, E., & Kip, T. (2026). Serum melatonin levels and their relationship with inflammation and oxidative stress in patients with diabetic nephropathy: a cross-sectional case–control study. BMC Endocrine Disorders, 26(1), Article 311. https://doi.org/10.1186/s12902-026-02634-y

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02634-y

Keywords: melatonin, diabetic nephropathy, type 2 diabetes, oxidative stress, total antioxidant status, total oxidant status, C-reactive protein, systemic inflammation, biomarker, kidney disease, case-control study, endocrinology

The kidney’s filtering units, the glomeruli, depend on a specialized layer of cells called podocytes. These cells wrap around the glomerular capillaries with interdigitating foot processes, forming slit diaphragms that act as the final, exquisitely selective barrier preventing albumin and other precious proteins from leaking into the urine. Podocytes are terminally differentiated epithelial cells; once damaged, they do not readily regenerate. One of the most consequential forms of podocyte injury is a process known as epithelial-to-mesenchymal transition, or EMT, in which these highly specialized epithelial cells lose their characteristic architecture and adhesion molecules and begin expressing mesenchymal markers such as N-cadherin, vimentin, and fibronectin. The transformed cells become motile, detach from the glomerular basement membrane, and contribute to the fibrotic scarring that progressively chokes off renal function. Prior work has implicated the TGF-beta signaling pathway, and its intracellular mediator SMAD3, as a central driver of this transition in the diabetic kidney.

The Harbin team began not in the laboratory but in the data. By integrating transcriptomic datasets from public repositories, they searched for RNA-binding proteins that were aberrantly expressed in diabetic kidney tissue, and PTBP3 emerged as a standout candidate. Polypyrimidine tract-binding protein 3 is a member of a family of proteins that bind specific sequence motifs in messenger RNA molecules, influencing their stability, translation, and alternative splicing. PTBP3 has attracted increasing attention in oncology research, where it has been shown to promote epithelial-to-mesenchymal transition and metastasis in lung adenocarcinoma, drive growth in colorectal and gastric cancers, and modulate immune escape in gallbladder cancer. Its role in kidney disease, however, had remained essentially unexplored, making the new findings a notable expansion of the protein’s known biological territory.

To confirm that the computational signal reflected real biology, the researchers turned to animal and cell models. In mice made diabetic by injection of streptozotocin, a compound that selectively destroys insulin-producing beta cells and reliably induces hyperglycemia, PTBP3 levels rose in kidney tissue. The same elevation appeared in podocytes grown in culture and exposed to high glucose concentrations, the standard in vitro model of diabetic cellular stress. These convergent observations, in vivo and in vitro, established that PTBP3 upregulation is a reproducible feature of the diabetic kidney environment rather than an artifact of any single experimental system, and positioned the protein as a plausible participant in disease pathogenesis.

The decisive experiment came next. The team knocked down PTBP3 in diabetic mice and monitored the classic functional readouts of kidney injury. The results were striking: 24-hour urinary protein excretion, a direct measure of the damaged filtration barrier, was significantly reduced in the knockdown animals. Serum creatinine and blood urea nitrogen, the two workhorse clinical markers of declining kidney clearance, were also substantially attenuated compared with diabetic controls. In other words, removing this single RNA-binding protein preserved measurable kidney function in the face of ongoing diabetes.

Histological analysis told a matching structural story. Under the microscope, the kidneys of diabetic mice typically show glomerular hypertrophy, expansion of the mesangial matrix that crowds the filtering tuft, and the deposition of collagen-rich fibrotic tissue. In the PTBP3 knockdown animals, all of these pathological features were ameliorated. Renal fibrosis was reduced, and the glomerular architecture was better preserved. The researchers further demonstrated that PTBP3 silencing inhibited the epithelial-to-mesenchymal transition of podocytes in the diabetic mice, an effect visible at the molecular level as restored expression of E-cadherin, the epithelial adhesion molecule that anchors podocytes in place, alongside reduced expression of the mesenchymal markers N-cadherin, vimentin, and fibronectin. Cultured podocytes subjected to high glucose showed the same pattern, reinforcing the consistency of the mechanism across model systems.

The mechanistic core of the paper lies in how PTBP3 exerts these effects, and here the authors provide a satisfying molecular explanation centered on SMAD3, the transcriptional mediator of TGF-beta signaling that has long been associated with fibrotic disease. Using dual-luciferase reporter assays and RNA immunoprecipitation, the team showed that PTBP3 physically interacts with the 3-prime untranslated region of SMAD3 messenger RNA. This interaction stabilizes the transcript, increasing the total amount of SMAD3 protein produced and, consequently, the levels of its phosphorylated, active form. In effect, PTBP3 acts as a post-transcriptional amplifier: by protecting SMAD3 mRNA from degradation, it boosts the signaling output of the TGF-beta pathway, which in turn drives podocytes toward the mesenchymal, fibrosis-promoting state. When PTBP3 is removed, SMAD3 expression falls, phosphorylation declines, and the EMT program loses its principal engine.

This finding places PTBP3 within a growing map of post-transcriptional regulation in diabetic kidney disease. The SMAD3 axis itself is well established: genetic deletion of Smad3 has previously been shown to prevent renal fibrosis and inflammation in models of type 2 diabetic nephropathy, and multiple microRNAs and circular RNAs have been described that modulate SMAD3 expression in mesangial cells and podocytes. What the new study adds is a specific RNA-binding protein that tunes the pathway at the level of mRNA stability, a layer of control that has been harder to drug than receptors or kinases but is increasingly recognized as a rich source of therapeutic targets. The parallel with cancer biology is also instructive, since PTBP3 has been repeatedly linked to TGF-beta-driven EMT in tumors, suggesting that the protein operates a conserved program of epithelial plasticity that the diabetic kidney co-opts for pathological remodeling.

The clinical implications, while still distant, are worth considering carefully. Diabetic nephropathy affects an enormous fraction of the growing global population with diabetes, and a substantial share of patients progress to dialysis or transplantation despite current best care. A target that acts upstream of SMAD3, and that demonstrably reduces proteinuria and preserves histology in a diabetic mouse model, represents the kind of mechanistic entry point that could eventually yield new drug classes, whether antisense oligonucleotides, small molecules that disrupt the PTBP3-SMAD3 mRNA interaction, or delivery strategies aimed specifically at podocytes. The authors note that PTBP3 knockdown ameliorated renal fibrosis and preserved renal function, underscoring the therapeutic potential of targeting podocyte epithelial-mesenchymal transition in diabetic nephropathy. At the same time, the usual caveats apply: mouse models of streptozotocin-induced diabetes capture only part of human diabetic kidney disease, and PTBP3’s roles in other tissues, including its documented effects in hematopoietic and endothelial biology, will need to be weighed against any systemic intervention.

For now, the study stands as a clear demonstration that the fate of the kidney’s filtration barrier can be steered by a single post-transcriptional regulator. By tracing a line from public transcriptomic data through diabetic mice and glucose-stressed podocytes down to a specific interaction between an RNA-binding protein and the untranslated region of a fibrotic transcription factor, the Harbin researchers have connected a molecular mechanism to clinically meaningful outcomes: less protein in the urine, lower creatinine, less scarring, better-preserved glomeruli. If those findings can be replicated in additional models and extended toward human tissue validation, PTBP3 may join the short list of molecules that clinicians watch as potential handles on one of diabetes’ most feared complications. The work was supported by the Basic Scientific Research Business Expenses Project of Colleges and Universities in Heilongjiang Province, and all animal experiments were approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University.

Subject of Research: The role of the RNA-binding protein PTBP3 in Smad3-dependent podocyte injury and fibrosis in diabetic nephropathy

Article Title: PTBP3 promotes diabetic nephropathy via Smad3-dependent podocyte-mesenchymal transition

Article References: Li, Y., Fu, Y., Wang, X., Ma, X., Cong, G., & Sui, M. (2026). PTBP3 promotes diabetic nephropathy via Smad3-dependent podocyte-mesenchymal transition. Molecular Biology Reports, 53(1), Article 1628. https://doi.org/10.1007/s11033-026-12788-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12788-6

Keywords: diabetic nephropathy, PTBP3, podocytes, SMAD3, epithelial-mesenchymal transition, renal fibrosis, RNA-binding proteins, TGF-beta signaling, chronic kidney disease, proteinuria, mRNA stability, kidney disease

The study drew on the PHDA Diabetes Complications Data Set maintained by the National Population Health Science Data Center in China. The investigators, Bin Yang of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and Penglu Yang of the same institution’s First Clinical School, assembled records from patients treated between January 1, 2018, and December 31, 2022. Crucially, they used a predefined 1:1 matching structure: exactly 1,500 patients with diabetic retinopathy and 1,500 without. This balanced design gives the comparison considerable statistical power, because the two groups contribute equally to every estimate and the analysis is not skewed by an overabundance of one type of patient.

The physiological logic behind the findings rests on the shared vulnerability of small blood vessels to chronic hyperglycemia. Diabetic retinopathy develops when persistently elevated blood glucose damages the delicate capillaries that nourish the retina, causing them to leak, become blocked, and eventually grow abnormally. The kidneys contain similarly fine capillary networks in their filtering units, the glomeruli, and the nerves and arteries of the lower limbs are also exposed to the same metabolic assault. Because the retina is the only place in the body where capillaries can be directly visualized noninvasively, ophthalmologists have long speculated that the eye might serve as a window onto the systemic state of the vasculature. The new data lend quantitative weight to that idea.

The numbers are striking. Diabetic nephropathy was present in 60.07 percent of patients with retinopathy but only 24.93 percent of those without, a nearly two-and-a-half-fold difference in raw prevalence. Chronic kidney disease, defined by sustained impairment of kidney filtration function, affected 10.60 percent of the retinopathy group compared with just 1.60 percent of the comparison group, roughly a six-fold gap. Lower extremity artery disease, a manifestation of atherosclerosis in the vessels supplying the legs, was found in 23.73 percent of retinopathy patients versus 7.93 percent of the others. All three differences were highly statistically significant, with p values below 0.001, meaning the probability that they arose by chance alone is vanishingly small.

Beyond categorical diagnoses, the study revealed measurable differences in basic clinical chemistry. Patients with retinopathy had higher glycated hemoglobin, reflecting poorer long-term glucose control, as well as elevated blood pressure, higher serum creatinine, and higher blood urea levels. Most telling was the estimated glomerular filtration rate, or eGFR, a standard index of kidney function calculated from age, sex, and serum creatinine. The retinopathy group averaged 78.95 milliliters per minute per 1.73 square meters of body surface area, compared with 93.05 in the non-retinopathy group. That fifteen-point difference indicates substantially reduced kidney filtration capacity and was statistically significant at the p < 0.001 level.

To move from raw prevalence to adjusted risk, the researchers employed multivariable logistic regression, a statistical technique that estimates the association between an exposure and an outcome while accounting for other variables that could confound the relationship. Here, the models adjusted for age, sex, fasting blood glucose, and HbA1c, the two most important glycemic measures. After adjustment, diabetic retinopathy remained independently associated with lower extremity artery disease with an odds ratio of 3.914, meaning retinopathy patients had nearly four times the odds of leg artery disease. The odds ratio for chronic kidney disease was 2.131, and for diabetic nephropathy it was 1.952. In each case the 95 percent confidence intervals, which ranged from roughly 1.26 to 5.09 across the three outcomes, excluded the null value of 1, indicating statistically robust associations.

One result stands out as counterintuitive: the study found an inverse association between diabetic retinopathy and coronary heart disease, with an odds ratio of 0.507. In other words, patients with retinopathy were about half as likely to have documented coronary heart disease as those without. This is surprising because both conditions are linked to diabetic vascular injury, and much prior literature has posited that retinopathy marks generalized atherosclerotic risk. The authors of the study themselves urge caution in interpreting this finding, noting that the cross-sectional design, the predefined sampling structure of the dataset, and the absence of certain important confounder variables all limit the strength of any causal or directional inference. The inverse coronary signal may reflect selection effects, differences in diagnostic workup between groups, or genuine pathophysiological divergence between microvascular and macrovascular disease, and it will require confirmation in longitudinal cohorts.

The methodological caveats deserve emphasis for readers weighing the clinical implications. A cross-sectional study captures a single moment in time, so it can establish that retinopathy and kidney or leg artery disease co-occur more often than expected, but it cannot prove that one causes the other or even establish the temporal sequence. It is biologically plausible that shared exposure to hyperglycemia, hypertension, and dyslipidemia drives all three conditions in parallel rather than retinopathy somehow triggering renal or peripheral arterial damage. Furthermore, the 1:1 sampling design, while statistically efficient, means the prevalence figures within the dataset do not represent the true prevalence in the general diabetic population, since equal numbers of retinopathy and non-retinopathy patients were deliberately selected. The authors also acknowledge that key confounders such as diabetes duration, smoking status, and medication use were unavailable in the dataset.

Despite these limitations, the study carries a practical message that clinicians and patients can act on today. Diabetic retinopathy is typically diagnosed during routine dilated eye examinations, which many patients with type 2 diabetes already undergo annually. If the presence of retinopathy meaningfully raises the probability of undetected nephropathy or lower extremity artery disease, then an eye clinic finding could serve as an efficient triage signal, prompting intensified screening of kidney function through urine protein measurements and eGFR monitoring, and of leg circulation through ankle-brachial index testing. Early detection of diabetic nephropathy allows interventions such as renin-angiotensin system blockers and newer agents like SGLT2 inhibitors to slow progression, while identifying peripheral artery disease early can prevent the catastrophic outcomes of foot ulcers and amputations.

The broader significance of the work lies in its contribution to a growing body of evidence that diabetic complications should be understood as a systemic syndrome rather than a collection of organ-specific diseases. With more than 140 million people living with diabetes in China and hundreds of millions worldwide, tools that help stratify risk cheaply and early have enormous public health value. The retinal examination, already a cornerstone of diabetes care, may deserve recognition as one of the most informative single data points in the entire clinical assessment. Future longitudinal studies, ideally with repeated retinal imaging and serial kidney and vascular measurements, will be needed to confirm whether the eye truly functions as a predictive sentinel for the rest of the diabetic body, and whether the unexpected inverse coronary finding holds up under scrutiny.

Subject of Research: Associations between diabetic retinopathy and systemic complications in type 2 diabetes

Article Title: Associations between diabetic retinopathy and systemic complications in patients with type 2 diabetes mellitus: a retrospective cross-sectional analysis of the PHDA diabetes complications data set in China

Article References: Yang, B., & Yang, P. (2026). Associations between diabetic retinopathy and systemic complications in patients with type 2 diabetes mellitus: a retrospective cross-sectional analysis of the PHDA diabetes complications data set in China. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02644-w

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02644-w

Keywords: diabetic retinopathy, type 2 diabetes, diabetic nephropathy, chronic kidney disease, lower extremity artery disease, coronary heart disease, eGFR, HbA1c, cross-sectional study, diabetes complications, microvascular disease, China

Diabetic kidney disease is the leading cause of chronic kidney failure worldwide, and its burden is expanding in lockstep with the global epidemic of type 2 diabetes. In Egypt, where diabetes prevalence ranks among the highest in the Middle East and North Africa, the clinical stakes are particularly high. Yet the diagnostic toolkit for diabetic nephropathy, the kidney-specific complication of diabetes, has remained stubbornly crude. Physicians typically rely on the urinary albumin-to-creatinine ratio, or UACR, a measure of how much of the protein albumin leaks into the urine, along with estimated glomerular filtration rate, or eGFR, which gauges how well the kidneys filter blood. Both markers have well-known blind spots. Albuminuria can fluctuate with infection, exercise, and glycemic control, and some patients lose filtration capacity without ever spilling significant albumin. The search for a more reliable, earlier, and more specific indicator has therefore become something of a holy grail in nephrology.

Long noncoding RNAs have emerged as unexpected candidates. These molecules, typically longer than two hundred nucleotides, do not code for proteins but instead participate in regulating gene expression, chromatin structure, and cellular signaling. In the kidney, several lncRNAs have been implicated in the fibrotic and inflammatory cascades that progressively scar the delicate filtering units known as glomeruli. PVT1, located on chromosome 8, first attracted attention in cancer biology, where its overexpression drives proliferation in lymphomas and other malignancies. More recently, genetic studies have linked a region near PVT1 to susceptibility to diabetic nephropathy, and experimental work has suggested that the RNA contributes to renal cell injury under high-glucose conditions. What remained uncertain was whether PVT1 levels measurable in the blood track the clinical severity of kidney damage in a real-world patient population.

To answer that question, the Cairo-based team enrolled eighty adults and divided them into four groups of twenty each. Three groups consisted of patients with type 2 diabetes, stratified by their urinary albumin-to-creatinine ratio into those with normal albumin excretion, moderately increased albuminuria, and severely increased albuminuria, the standard staging categories used to grade diabetic kidney disease. The fourth group comprised healthy controls. The researchers also performed fundus examinations to classify the diabetic participants according to whether they had diabetic retinopathy, an eye complication that often parallels kidney involvement. Every participant underwent a full clinical and laboratory workup, and serum levels of PVT1 were quantified using real-time polymerase chain reaction, a technique that amplifies and measures specific RNA sequences with high sensitivity.

The results were striking. Serum PVT1 expression was markedly elevated across the diabetic groups compared with the healthy controls, and within the diabetic cohort, levels climbed with disease stage: patients with severely increased albuminuria showed significantly higher PVT1 than those with normal urinary albumin. In other words, the RNA signal in the blood rose in step with the conventional staging of kidney damage, suggesting that PVT1 is not merely a binary flag for the presence of disease but a graded readout of its progression.

The correlation analysis deepened the picture. PVT1 levels showed a significant positive association with UACR, serum creatinine, age, body mass index, fasting blood glucose, two-hour postprandial glucose, and glycated hemoglobin, or HbA1c. The links to glucose measures are particularly intriguing, because they hint that PVT1 expression responds to the glycemic environment itself, the very insult that drives diabetic tissue damage. The positive association with creatinine, a waste product that accumulates when filtration falters, reinforces the connection to declining renal function. Conversely, PVT1 correlated negatively with eGFR, the best available summary of kidney filtering capacity, as well as with alanine aminotransferase, a liver enzyme, and platelet count. The negative correlations with eGFR and platelets fit a pattern in which advancing kidney disease and its systemic complications are mirrored by falling values of protective or homeostatic markers.

Perhaps the most consequential finding came from the regression analysis. When the researchers tested which variables independently predicted proteinuria, the abnormal leakage of protein into urine that defines progressive diabetic nephropathy, PVT1 stood alone as the sole independent predictor among the diabetic patients. That means that even after accounting for age, glycemic control, and other clinical factors, the serum RNA level carried predictive information about kidney involvement that the other measures did not. If confirmed in larger and more diverse cohorts, this property could make PVT1 a genuinely additive biomarker, one that complements rather than duplicates the existing panel.

The study’s design and context deserve careful attention. It was conducted at Kasr Al-Ainy Hospital, the historic teaching hospital of Cairo University’s Faculty of Medicine, and approved by the institution’s ethical committee with oral and written informed consent obtained from participants or their eligible relatives, in accordance with the Declaration of Helsinki. The cohort size of eighty, while adequate for detecting the reported differences, is modest, and the cross-sectional design captures a single moment in time rather than following patients forward. A cross-sectional correlation between PVT1 and kidney stage cannot by itself prove that the RNA drives disease progression or that it predicts future decline; it establishes association. Prospective studies that track PVT1 levels over years, alongside serial measurements of eGFR and albuminuria, will be needed to establish whether the molecule can forecast deterioration before conventional markers move.

There are also mechanistic questions that the clinical data raise but do not resolve. Is serum PVT1 merely a passive shed product of injured kidney cells, a molecular echo of tissue damage, or does it actively participate in the fibrotic and inflammatory processes that destroy glomeruli? Experimental evidence from cell and animal models suggests the latter is plausible, with PVT1 implicated in pathways of renal cell apoptosis and extracellular matrix accumulation under diabetic conditions. If the RNA is causally involved, it becomes not just a biomarker but a therapeutic target, and the authors of the new study explicitly frame it as such. Silencing or sequestering specific lncRNAs is technically feasible with antisense oligonucleotides and related technologies, several of which have already reached clinical use in other organ systems, though delivering such drugs safely to kidney tissue in diabetes remains a distant goal.

For now, the practical significance lies in diagnostics. A blood-based RNA marker could be measured alongside routine chemistry, potentially catching kidney involvement earlier or stratifying risk more finely than urine albumin alone. It could also help resolve the vexing subgroup of diabetic patients whose kidney function declines without marked albuminuria, a pattern increasingly recognized as its own clinical entity. The Egyptian setting matters as well: populations differ in genetic background, environmental exposures, and healthcare access, and biomarkers validated in one population do not automatically transfer to another. By demonstrating the PVT1 signal in an Egyptian cohort, the study extends the geographic and ethnic reach of the evidence, though replication in independent cohorts within Egypt and beyond remains essential before any clinical deployment.

The broader lesson is about where medicine is looking for its next generation of tests. For decades, clinical chemistry has been dominated by proteins and metabolites, molecules whose abundance reflects the downstream consequences of disease. Noncoding RNAs occupy a different layer of the biological hierarchy, closer to the regulatory programs that orchestrate tissue response to injury. Their dysregulation can be specific to particular pathological pathways in ways that generic markers like creatinine are not. The Cairo study, with its demonstration that a single serum lncRNA rises with diabetic kidney disease severity and independently predicts proteinuria, offers a concrete example of that promise. It also illustrates the standard trajectory of biomarker science: an intriguing association in a well-characterized cohort, followed by the harder work of validation, mechanistic dissection, and prospective testing. If PVT1 survives that gauntlet, the dark matter of the genome may earn a permanent place in the nephrologist’s toolkit, and patients with diabetes may gain an earlier, clearer warning that their kidneys are under siege.

Subject of Research: Serum long noncoding RNA PVT1 as a biomarker of diabetic nephropathy severity in Egyptian patients with type 2 diabetes

Article Title: Serum long noncoding RNA human plasmacytoma variant translocation 1 (PVT1) expression levels in Egyptians type 2 diabetic patients and its correlation with severity of diabetic nephropathy

Article References: Tarabay, A., Shaker, O. G., ElSayed, N. M., Allam, D., Abdellatef, A., & Attia, M. (2026). Serum long noncoding RNA human plasmacytoma variant translocation 1 (PVT1) expression levels in Egyptians type 2 diabetic patients and its correlation with severity of diabetic nephropathy. BMC Endocrine Disorders, 26(1), Article 275. https://doi.org/10.1186/s12902-026-02449-x

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02449-x

Keywords: type 2 diabetes, diabetic kidney disease, diabetic nephropathy, long noncoding RNA, PVT1, biomarker, albuminuria, proteinuria, eGFR, real-time PCR, Egypt, Cairo University